Long-Acting Antibody Combo Reduced Risk of Symptomatic COVID-19 in Phase 3 Trials
New analyses were announced from the phase 3 PROVENT and TACKLE trials evaluating the efficacy and safety of AZD7442 for the prevention of COVID-19.
AZD7442 is a combination of 2 long-acting monoclonal antibodies, tixagevimab and cilgavimab, derived from B-cells donated by convalescent patients who were infected with the SARS-CoV-2 virus. The investigational antibodies are designed to bind to distinct sites on the SARS-CoV-2 spike protein with an extended half-life and reduced Fc receptor and complement C1q binding. At a median follow-up of 6 months, results showed that AZD7442 achieved an 83% risk reduction of developing symptomatic COVID-19 compared with placebo. There were no cases of severe COVID-19 or COVID-19-related deaths in the AZD7442 treatment arm at either the primary or 6-month analyses compared with 2 additional cases of severe COVID-19 in the placebo arm for a total of 5 cases, including 2 deaths. These results support the previous analysis from August 2021, wich showed a 77% risk reduction of developing symptomatic COVID-19.
Lees dit artikel verder op: Long-Acting Antibody Combo Reduced Risk of Symptomatic COVID-19 in Phase 3 Trials (empr.com)
